In this study, we found that sclerostin serum levels increased after 12-month follow-up to a significant greater extent in patients treated with higher GC doses; further, serum levels of sclerostin and DKK were negatively associated to TBS and a positive correlation between serum sclerostin levels and cumulative GC dose was observed. This evidence concerns the gene SOST and Townes-Brocks syndrome.